+971 56 274 1787WhatsApp
infectious-immune-conditions ConditionNeurological

Scleroderma & Systemic Sclerosis

"Tight, hard, or shiny skin that feels like it's shrinking or pulling"

15+
Days/Month
50-70%
Medication Overuse
2-3x
Stroke Risk
Reversible
With Treatment
Understanding Your Condition

What is Chronic Migraine?

Scleroderma (also called Systemic Sclerosis) is a chronic autoimmune disease characterized by excessive collagen production causing hardening and tightening of the skin and connective tissues. In systemic forms, it affects internal organs including the lungs, heart, kidneys, and digestive tract. The condition affects approximately 75,000-100,000 people in the United States, with women being 4 times more likely to develop it than men. The disease typically manifests between ages 30-50 and progresses slowly, with symptoms ranging from mild skin thickening to life-threatening organ involvement.

Healthy Function

What your body should do

In a healthy individual, the immune system maintains tolerance and does not attack the body's own tissues. Fibroblasts (cells that produce collagen) function normally, producing just enough collagen to maintain skin elasticity, wound healing, and tissue repair. Blood vessels maintain normal tone and respond appropriately to temperature changes, keeping fingers warm and well-perfused. The digestive tract has normal motility, allowing smooth passage of food. The lungs maintain elasticity for normal breathing. The heart pumps efficiently without restriction. The kidneys regulate blood pressure and fluid balance without damage. The extracellular matrix maintains proper balance between collagen production and breakdown.

When Things Go Wrong

Signs of chronification

  • Pain threshold lowers over time
  • More frequent attacks
  • Brain stays in alert mode
  • Medication stops working
Development Process

How This Develops

Understanding the biological mechanisms helps us target the root cause

Point 1

Understanding the mechanism helps us target the root cause rather than just treating symptoms.

Commonly Associated

Conditions That Occur Together

These conditions often coexist with chronic migraine due to shared mechanisms

Related Condition

Raynaud's Phenomenon

Present in 90-95% of scleroderma patients; vascular dysfunction causes exaggerated vasoconstriction in response to cold or stress; can precede other symptoms by years

Related Condition

Pulmonary Hypertension

Vascular changes in lung arteries cause increased pressure; more common in limited cutaneous form with anti-centromere antibodies; leads to right heart failure

Related Condition

Interstitial Lung Disease

Fibrosis of lung tissue reduces oxygen exchange; associated with anti-Scl-70 antibodies; leading cause of mortality in diffuse cutaneous form

Related Condition

Gastroesophageal Reflux Disease (GERD)

Smooth muscle dysfunction in lower esophageal sphincter causes severe reflux; esophageal dysmotility impairs clearance; can lead to Barrett's esophagus

Related Condition

Small Intestinal Bacterial Overgrowth (SIBO)

Intestinal dysmotility allows bacterial proliferation; causes bloating, malabsorption, and nutrient deficiencies

Related Condition

Sjögren's Syndrome

Autoimmune attack on moisture-producing glands; common overlap with scleroderma; causes dry eyes and dry mouth

Related Condition

Autoimmune Thyroiditis

Shared autoimmune mechanisms; Hashimoto's thyroiditis commonly co-occurs with scleroderma

Related Condition

Primary Biliary Cholangitis

Autoimmune bile duct destruction; more common in limited cutaneous form with anti-centromere antibodies

Related Condition

Inflammatory Arthritis

Joint inflammation and pain; may overlap with rheumatoid arthritis features

Related Condition

Carpal Tunnel Syndrome

Wrist tissue swelling compresses median nerve; common early symptom from tissue edema

Differential Diagnoses

Conditions to Rule Out

These conditions can present similarly but have distinct features

Condition

Nephrogenic Systemic Fibrosis

Overlapping

Skin thickening and hardening

Key Difference

History of gadolinium contrast exposure in kidney disease; no Raynaud's phenomenon; no autoantibodies

Condition

Eosinophilic Fasciitis

Overlapping

Skin thickening, joint contractures

Key Difference

Rapid onset; prominent eosinophilia on blood tests; spares hands and face; no Raynaud's; different histology

Condition

Chronic Graft-Versus-Host Disease

Overlapping

Skin fibrosis, sicca symptoms

Key Difference

History of bone marrow or stem cell transplant; different pattern of skin involvement

Condition

Diabetic Sclerodactyly

Overlapping

Thickening of finger skin

Key Difference

History of diabetes; limited to hands; peau d'orange appearance; no systemic features

Condition

Mixed Connective Tissue Disease

Overlapping

Raynaud's, arthritis, esophageal dysmotility

Key Difference

High titer anti-U1-RNP antibodies; features of multiple autoimmune diseases; milder course

Condition

Undifferentiated Connective Tissue Disease

Overlapping

Raynaud's, mild symptoms

Key Difference

Symptoms present but don't meet criteria for specific disease; may evolve into scleroderma

Condition

Systemic Lupus Erythematosus

Overlapping

Fatigue, arthritis, Raynaud's

Key Difference

Different rash patterns; anti-dsDNA and anti-Sm antibodies; no significant skin fibrosis

Condition

Dermatomyositis

Overlapping

Skin changes, muscle weakness

Key Difference

Heliotrope rash, Gottron's papules; proximal muscle weakness; elevated muscle enzymes

Root Causes

What's Driving Your Migraines

Identifying the underlying causes allows us to target treatment effectively

1

Genetic Predisposition

Modest genetic component; 1.5-2% familial aggregation

Family history of autoimmune disease; HLA typing (HLA-DRB1*11, HLA-DQA1); non-HLA genes (IRF5, STAT4, CD247)

2

Environmental Triggers

May initiate disease in susceptible individuals

History of silica exposure (miners, foundry workers); solvent exposure; epoxy resins; viral infections

3

Viral Infections

May trigger autoimmune response through molecular mimicry

EBV serology; CMV antibodies; parvovirus B19; retroviruses

4

Epigenetic Changes

DNA methylation patterns altered in scleroderma fibroblasts

Research settings; family history of environmental exposures

5

Microchimerism

Fetal cells persisting in maternal circulation may trigger graft-versus-host-like reaction

History of pregnancies; more common in women with prior pregnancies

6

Oxidative Stress

Free radical damage to endothelial cells initiates vascular injury

Advanced lipid peroxidation markers; antioxidant status; isoprostanes

7

Gut Dysbiosis

Altered microbiome may influence immune regulation

Comprehensive stool analysis; intestinal permeability testing; SIBO breath testing

8

Chronic Stress and Trauma

Stress may trigger or exacerbate autoimmune processes

Stress history; cortisol patterns; HPA axis function

Lab Assessment

Key Laboratory Markers

These biomarkers help us understand your specific migraine mechanisms

Test
Normal Range
Optimal Range
Clinical Significance
ANA (Antinuclear Antibodies)
Normal:Negative (<1:40 titer) titer
Optimal:Negative titer
Positive in 90-95% of scleroderma patients; indicates autoimmune activity
Anti-Scl-70 (Anti-Topoisomerase I)
Normal:Negative index
Optimal:Negative index
Specific for diffuse cutaneous systemic sclerosis; associated with lung fibrosis
Anti-Centromere Antibodies (ACA)
Normal:Negative index
Optimal:Negative index
Specific for limited cutaneous systemic sclerosis (CREST); associated with pulmonary hypertension
Anti-RNA Polymerase III
Normal:Negative index
Optimal:Negative index
Associated with diffuse disease and scleroderma renal crisis risk
ESR (Erythrocyte Sedimentation Rate)
Normal:0-20 mm/hr (women), 0-15 mm/hr (men) mm/hr
Optimal:<10 mm/hr mm/hr
Non-specific marker of inflammation; may be elevated in active disease
CRP (C-Reactive Protein)
Normal:<10 mg/L mg/L
Optimal:<3 mg/L mg/L
Acute phase reactant; elevated in active inflammation
Complete Blood Count (CBC)
Normal:Varies by parameter various
Optimal:All parameters within optimal ranges various
May show anemia of chronic disease, thrombocytopenia, or leukopenia
Creatinine and eGFR
Normal:Creatinine 0.6-1.2 mg/dL mg/dL
Optimal:Creatinine <1.0 mg/dL, eGFR >90 mg/dL
Monitor kidney function; elevation may indicate renal crisis
Urinalysis
Normal:No protein, no blood various
Optimal:No abnormalities various
Proteinuria or hematuria may indicate kidney involvement
Pulmonary Function Tests (PFTs)
Normal:>80% predicted % predicted
Optimal:>90% predicted % predicted
Reduced DLCO indicates lung fibrosis; restrictive pattern common
NT-proBNP or BNP
Normal:<125 pg/mL pg/mL
Optimal:<100 pg/mL pg/mL
Elevated in pulmonary hypertension and heart involvement
6-Minute Walk Test
Normal:400-700 meters meters
Optimal:>500 meters meters
Reduced distance or oxygen desaturation indicates cardiopulmonary involvement
Cost of Waiting

What Happens If Left Untreated

Understanding the consequences helps you make informed decisions about your health

Progressive Skin Fibrosis

Months to years

Severe limitation of joint movement; contractures; difficulty with daily activities; cosmetic disfigurement

Pulmonary Fibrosis

2-10 years

Irreversible lung scarring; progressive shortness of breath; oxygen dependence; leading cause of death in diffuse form

Pulmonary Hypertension

Variable; can develop suddenly

Right heart failure; severely limited exercise capacity; high mortality without treatment

Scleroderma Renal Crisis

Can occur acutely

Malignant hypertension; acute kidney failure; requires dialysis; 50% mortality without prompt ACE inhibitor treatment

Heart Failure and Arrhythmias

Progressive

Myocardial fibrosis causes heart failure; conduction abnormalities; sudden cardiac death risk

Digital Amputation

Progressive vascular disease

Severe Raynaud's with digital ulcers progressing to gangrene; may require finger/toe amputation

Malnutrition and Cachexia

Progressive

Severe GI dysmotility leads to weight loss, vitamin deficiencies, muscle wasting

Aspiration Pneumonia

Acute risk

Esophageal dysmotility causes aspiration; recurrent infections; respiratory failure

Gastric Antral Vascular Ectasia (GAVE)

Progressive

Watermelon stomach causes chronic bleeding; iron deficiency anemia; may require transfusions

Increased Mortality

Over disease course

Standardized mortality ratio 3-7 times higher than general population; 10-year survival 50-80% depending on subtype

Time Matters

Don't wait for symptoms to worsen. Early intervention leads to better outcomes.

Diagnostic Approach

How is Chronic Migraine Diagnosed?

Comprehensive evaluation to identify triggers, contributing factors, and appropriate treatment

ANA with Reflex Panel

Purpose:

Screen for autoimmune disease

Positive in 90-95% of scleroderma; pattern suggests specific autoantibodies

Scleroderma-Specific Antibodies

Purpose:

Confirm diagnosis and subtype

Anti-Scl-70 (diffuse disease, lung fibrosis), Anti-centromere (limited disease, CREST), Anti-RNA Pol III (diffuse, renal crisis risk)

Modified Rodnan Skin Score (mRSS)

Purpose:

Assess skin fibrosis severity

Pinching skin at 17 body sites; score 0-51; tracks disease progression

High-Resolution CT of Chest

Purpose:

Detect interstitial lung disease

Ground glass opacities, reticular changes, honeycombing; extent of fibrosis

Echocardiogram with Estimated RVSP

Purpose:

Screen for pulmonary hypertension

Right ventricular systolic pressure; right heart function; pericardial effusion

Right Heart Catheterization

Purpose:

Confirm pulmonary hypertension

Gold standard; measures pulmonary artery pressures directly; assesses treatment response

Pulmonary Function Tests

Purpose:

Assess lung function

Reduced DLCO (gas exchange); restrictive pattern; monitors progression

6-Minute Walk Test

Purpose:

Functional assessment

Exercise capacity; oxygen desaturation with activity

Barium Swallow or Esophageal Manometry

Purpose:

Assess esophageal function

Dysmotility; reduced lower esophageal sphincter pressure; reflux

Gastric Emptying Study

Purpose:

Assess stomach motility

Delayed gastric emptying; gastroparesis

Renal Function Monitoring

Purpose:

Early detection of renal crisis

Rising creatinine; proteinuria; new hypertension

Nailfold Capillaroscopy

Purpose:

Assess microvascular changes

Giant capillaries, hemorrhages, avascular areas; diagnostic and prognostic value

Diet & Lifestyle

Supporting Your Treatment

Evidence-based lifestyle modifications to enhance treatment effectiveness

Anti-inflammatory diet: Emphasize omega-3 rich foods (wild salmon, sardines, walnuts, flaxseeds) to reduce inflammation

Antioxidant-rich foods: Colorful vegetables and fruits, especially berries, leafy greens, bell peppers - combat oxidative stress

Turmeric and ginger: Natural anti-inflammatory spices; use liberally in cooking

Vitamin C-rich foods: Citrus, kiwi, bell peppers - support collagen health and immune function

Avoid processed foods: Eliminate refined sugars, processed meats, artificial additives that promote inflammation

Limit sodium: Important for blood pressure control, especially with renal involvement

Small, frequent meals: Better tolerated with esophageal dysmotility and gastroparesis

Soft, moist foods: Easier to swallow with esophageal involvement

Stay upright after eating: Remain upright 2-3 hours after meals to reduce reflux

Adequate hydration: 8-10 glasses water daily; supports circulation and tissue health

Avoid alcohol: Can worsen reflux and interact with medications

Limit caffeine: May worsen Raynaud's phenomenon in some patients

Success Metrics

What Success Looks Like

Skin score stabilization or improvement (Modified Rodnan Skin Score)

Stable or improved pulmonary function tests (DLCO, FVC)

No evidence of pulmonary hypertension on echocardiogram

Stable renal function (creatinine, blood pressure)

Reduced frequency and severity of Raynaud's attacks

Healing of digital ulcers

Improved 6-minute walk distance

Reduced reflux symptoms

Maintained or improved joint range of motion

Stable or improved quality of life scores

No hospitalizations for disease flares

Ability to perform activities of daily living

Maintenance of nutritional status and healthy weight

Stable cardiac function

Common Questions

Frequently Asked Questions

Expertise Behind This Guide

Evidence-Based Information

Dr. Hafeel Afsar, DHA Licensed Integrative and Functional Medicine Practitioner Specialization: Autoimmune conditions, connective tissue disorders, vascular health Qualifications: Board-certified in Integrative Medicine, Advanced Rheumatology Training Experience: 15+ years treating autoimmune and fibrotic conditions with integrative protocols

References

  1. 1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009;360(19):1989-2003. doi:10.1056/NEJMra0806188 - Comprehensive review of scleroderma pathophysiology and treatment.
  2. 2. Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685-1699. doi:10.1016/S0140-6736(17)30933-9 - Current state of scleroderma diagnosis and management.
  3. 3. Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327-1339. doi:10.1136/annrheumdis-2016-209909 - Evidence-based treatment guidelines.
  4. 4. Herrick AL. Pathogenesis of Raynaud's phenomenon. Rheumatology (Oxford). 2005;44(5):587-596. doi:10.1093/rheumatology/keh552 - Mechanisms and management of Raynaud's.
  5. 5. Nihtyanova SI, Denton CP. Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol. 2010;6(2):112-116. doi:10.1038/nrrheum.2009.238 - Role of autoantibodies in prognosis.
  6. 6. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354(25):2655-2666. doi:10.1056/NEJMoa055120 - Landmark trial for scleroderma lung disease.

Ready to Find Relief from Chronic Migraines?

Our integrative approach has helped hundreds of patients find lasting relief from chronic migraines. Schedule your comprehensive assessment today.

500+ Patients Treated
15+ Years Experience
Integrative Approach